Patents by Inventor Heinz Lubenau

Heinz Lubenau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190183996
    Abstract: The present invention relates to a method for producing a DNA vaccine for cancer immunotherapy comprising at least the steps of (a) transforming an attenuated strain of Salmonella with at least one DNA molecule comprising at least one expression cassette encoding at least one antigen or at least one fragment thereof; (b) characterizing at least one transformed cell clone obtained in step (a); and (c) selecting at least one of the transformed cell clone(s) characterized in step (b) and further characterizing said at least one selected transformed cell clone. The present invention further relates to a DNA vaccine obtainable by the method according to the present invention.
    Type: Application
    Filed: July 12, 2017
    Publication date: June 20, 2019
    Inventor: Heinz Lubenau
  • Patent number: 10293037
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: May 21, 2019
    Assignee: VAXIMM AG
    Inventor: Heinz Lubenau
  • Publication number: 20190008936
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: May 31, 2018
    Publication date: January 10, 2019
    Applicant: Vaximm AG
    Inventor: Heinz Lubenau
  • Publication number: 20180250345
    Abstract: The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one further anti-cancer agent. The present invention further relates to a pharmaceutical composition comprising an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, wherein the pharmaceutical composition further comprises at least one further attenuated strain of Salmonella comprising at least one copy of a further DNA molecule comprising a further expression cassette encoding a tumor antigen or a tumor stroma antigen.
    Type: Application
    Filed: June 16, 2016
    Publication date: September 6, 2018
    Applicant: VAXIMM AG
    Inventor: Heinz Lubenau
  • Publication number: 20180163169
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Wilms' tumor Protein I. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: January 16, 2018
    Publication date: June 14, 2018
    Inventors: Heinz LUBENAU, Marco SPRINGER
  • Publication number: 20180153976
    Abstract: The present invention relates to an attenuated strain of Salmonella comprising a DNA molecule encoding CMV pp65. In particular, the present invention relates to the use of said attenuated strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: June 6, 2016
    Publication date: June 7, 2018
    Inventor: Heinz Lubenau
  • Patent number: 9920297
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Wilms' tumor Protein 1. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: March 20, 2018
    Assignee: VAXIMM AG
    Inventors: Heinz Lubenau, Marco Springer
  • Publication number: 20180064794
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: October 17, 2017
    Publication date: March 8, 2018
    Inventors: Marco SPRINGER, Heinz LUBENAU
  • Patent number: 9493738
    Abstract: This invention relates to a novel method for growing attenuated mutant Salmonella typhi strains lacking galactose epimerase activity and harboring a recombinant DNA molecule. The method comprises the step of culturing said Salmonella typhi strain without adding glucose to the medium during the fermentation with a starting glucose amount that is depleted before reaching the stationary phase. The invention further relates to attenuated mutant Salmonella typhi strains obtainable by said method and to an attenuated mutant Salmonella typhi strain harboring a recombinant DNA molecule encoding a VEGF receptor protein for use as a vaccine.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: November 15, 2016
    Assignee: VAXIMM AG
    Inventors: Heinz Lubenau, Holger Siede, Renate Janssen, Marco Springer
  • Publication number: 20160317634
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: December 17, 2014
    Publication date: November 3, 2016
    Applicant: Vaximm GMBH Mafinex-Technologiezentrum
    Inventors: Marco SPRINGER, Heinz LUBENAU
  • Patent number: 9468685
    Abstract: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: October 18, 2016
    Assignee: RATIOPHARM GMBH
    Inventors: Walter Hinderer, Heinz Lubenau
  • Publication number: 20160250311
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: May 18, 2016
    Publication date: September 1, 2016
    Inventor: Heinz Lubenau
  • Patent number: 9415098
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: August 16, 2016
    Assignee: VAXIMM AG
    Inventor: Heinz Lubenau
  • Publication number: 20160068801
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Wilms' tumor Protein 1. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: April 24, 2014
    Publication date: March 10, 2016
    Inventors: Heinz LUBENAU, Marco SPRINGER
  • Publication number: 20150165011
    Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
    Type: Application
    Filed: June 26, 2013
    Publication date: June 18, 2015
    Inventor: Heinz Lubenau
  • Patent number: 9050304
    Abstract: The present invention provides a glycopegylated G-CSF that is therapeutically active and which has pharmacokinetic parameters and properties that are improved relative to an identical, or closely analogous, G-CSF peptide that is not glycopegylated. Furthermore, the invention provides methods for mobilizing hematopoiesis in a subject, particularly a subject who has received or will receive radiation or chemotherapy treatment. The methods and compositions of the invention can further be used to prevent, alleviate and treat the myelosuppressive effects such therapies.
    Type: Grant
    Filed: April 1, 2008
    Date of Patent: June 9, 2015
    Assignee: ratiopharm GmbH
    Inventors: David A. Zopf, Heinz Lubenau
  • Publication number: 20150125420
    Abstract: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.
    Type: Application
    Filed: January 9, 2015
    Publication date: May 7, 2015
    Inventors: Walter Hinderer, Heinz Lubenau
  • Patent number: 8946161
    Abstract: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: February 3, 2015
    Assignee: Ratiopharm GmbH
    Inventors: Walter Hinderer, Heinz Lubenau
  • Publication number: 20140349274
    Abstract: This invention relates to a novel method for growing attenuated mutant Salmonella typhi strains lacking galactose epimerase activity and harboring a recombinant DNA molecule. The method comprises the step of culturing said Salmonella typhi strain without adding glucose to the medium during the fermentation with a starting glucose amount that is depleted before reaching the stationary phase. The invention further relates to attenuated mutant Salmonella typhi strains obtainable by said method and to an attenuated mutant Salmonella typhi strain harboring a recombinant DNA molecule encoding a VEGF receptor protein for use as a vaccine.
    Type: Application
    Filed: December 21, 2012
    Publication date: November 27, 2014
    Applicant: Vaximm AG
    Inventors: Heinz Lubenau, Holger Siede, Renate Janssen, Marco Springer
  • Publication number: 20140030214
    Abstract: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.
    Type: Application
    Filed: October 2, 2013
    Publication date: January 30, 2014
    Applicant: BIOGENERIX GMBH
    Inventors: Walter Hinderer, Heinz Lubenau